CN1701788A - 禽多核苷酸疫苗制剂 - Google Patents

禽多核苷酸疫苗制剂 Download PDF

Info

Publication number
CN1701788A
CN1701788A CNA2005100669793A CN200510066979A CN1701788A CN 1701788 A CN1701788 A CN 1701788A CN A2005100669793 A CNA2005100669793 A CN A2005100669793A CN 200510066979 A CN200510066979 A CN 200510066979A CN 1701788 A CN1701788 A CN 1701788A
Authority
CN
China
Prior art keywords
vaccine
plasmid
gene
virus
avian
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005100669793A
Other languages
English (en)
Chinese (zh)
Inventor
J-C·奥都尼特
A·布萨都恩
M·里威尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health France SAS
Original Assignee
Merial SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial SAS filed Critical Merial SAS
Publication of CN1701788A publication Critical patent/CN1701788A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255—Marek's disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/22011—Dicistroviridae
    • C12N2770/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CNA2005100669793A 1996-07-19 1997-07-16 禽多核苷酸疫苗制剂 Pending CN1701788A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR96/09339 1996-07-19
FR9609339A FR2751225B1 (fr) 1996-07-19 1996-07-19 Formule de vaccin polynucleotidique aviaire

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN97196561A Division CN1225685A (zh) 1996-07-19 1997-07-16 禽多核苷酸疫苗制剂

Publications (1)

Publication Number Publication Date
CN1701788A true CN1701788A (zh) 2005-11-30

Family

ID=9494451

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2005100669793A Pending CN1701788A (zh) 1996-07-19 1997-07-16 禽多核苷酸疫苗制剂
CN97196561A Pending CN1225685A (zh) 1996-07-19 1997-07-16 禽多核苷酸疫苗制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN97196561A Pending CN1225685A (zh) 1996-07-19 1997-07-16 禽多核苷酸疫苗制剂

Country Status (19)

Country Link
US (3) US6221362B1 (https=)
EP (2) EP1523992A1 (https=)
JP (2) JP2001503019A (https=)
KR (1) KR20000065258A (https=)
CN (2) CN1701788A (https=)
AR (1) AR013063A1 (https=)
AU (1) AU735184B2 (https=)
BR (1) BR9710495A (https=)
CA (1) CA2261343A1 (https=)
CO (1) CO4700304A1 (https=)
DE (1) DE69730839T2 (https=)
ES (1) ES2232876T3 (https=)
FR (1) FR2751225B1 (https=)
HU (1) HU224830B1 (https=)
ID (1) ID19475A (https=)
MA (1) MA24268A1 (https=)
NZ (1) NZ333779A (https=)
TN (1) TNSN97120A1 (https=)
WO (1) WO1998003659A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102719567A (zh) * 2012-07-05 2012-10-10 广东温氏食品集团有限公司 禽传染性支气管炎病毒h120毒株的pcr检测引物及检测方法
CN111727053A (zh) * 2018-01-26 2020-09-29 全国农业协同组合连合会 非人动物用抗原表面结合型脂质体疫苗
CN115089700A (zh) * 2022-05-25 2022-09-23 永州中古生物技术有限公司 一种抗β属冠状病毒的疫苗组合物及其应用

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751225B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
ZA978434B (en) * 1996-09-27 1998-03-26 Akzo Nobel Nv Inactivated vaccines.
US6468984B1 (en) * 1999-06-08 2002-10-22 Innovo Biotechnologies Ltd. DNA vaccine for protecting an avian against infectious bursal disease virus
WO2000077218A1 (en) * 1999-06-10 2000-12-21 Agricultural Research Council Vaccine for newcastle disease virus
AR031405A1 (es) * 2000-11-21 2003-09-24 Wyeth Corp Metodos y vacunas para conferir proteccion in ovo contra la rinotraqueitis del pavo
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
IL145397A0 (en) * 2001-09-12 2002-06-30 Yissum Res Dev Co Compositions and methods for treatment of cancer
US7615209B2 (en) 2001-09-12 2009-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions of NDV and methods of use thereof for treatment of cancer
US7029681B2 (en) * 2002-03-08 2006-04-18 Schweitzer Chemical Corporation Multiple and multivalent DNA vaccines in ovo
US7037506B2 (en) * 2002-03-08 2006-05-02 Schweltzer Chemical Corporation Ltd. Vaccine accelerator factor (VAF) for improvement of vaccinations in poultry
US20060121447A1 (en) * 2002-04-12 2006-06-08 Ilaria Capua Purified subfragment codifying for neuroaminidase, recombinant neuroaminidase and its use in zooprophylaxis
BRPI0315340B1 (pt) 2002-10-15 2016-03-15 Pah W Llc processo para detectar o vírus da doença de marek (mdv) em uma amostra derivada de uma ou mais penas de ave
EP1606419A1 (en) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
US20050214316A1 (en) 2003-11-13 2005-09-29 Brown Thomas P Methods of characterizing infectious bursal disease virus
MXPA06009452A (es) 2004-02-19 2007-03-15 Univ Alberta Polimorfismos del promotor de leptin y sus usos.
PT1881845E (pt) 2005-04-25 2010-05-31 Merial Ltd Vacinas de vírus nipah
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
DE102005040812A1 (de) * 2005-08-27 2007-03-15 Few Fahrzeugelektrikwerk Gmbh & Co. Kg Elektrischer Anschluss sowie Verfahren zu dessen Verbindung mit der Scheibe eines Kraftfahrzeugs
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
EP3147296A1 (en) 2005-11-14 2017-03-29 Merial, Inc. Gene therapy for renal failure
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
US20080274137A1 (en) * 2007-05-02 2008-11-06 Jean Christophe Francis Audonnet DNA plasmids having improved expression and stability
UA100692C2 (ru) 2007-05-02 2013-01-25 Мериал Лимитед Днк-плазмиды, имеющие повышенную экспрессию и стабильность
CN102046522A (zh) * 2008-06-03 2011-05-04 旭硝子株式会社 核—壳粒子的制造方法、核—壳粒子、中空粒子的制造方法、涂料组合物及物品
RU2559527C2 (ru) 2008-11-28 2015-08-10 Мериал Лимитед Рекомбинантная вакцина от птичьего гриппа и её применение
WO2010115133A2 (en) 2009-04-03 2010-10-07 Merial Limited Newcastle disease virus vectored avian vaccines
CN103260643A (zh) 2009-12-28 2013-08-21 梅里亚有限公司 重组ndv抗原及其用途
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
ES2617743T3 (es) 2010-03-12 2017-06-19 Merial, Inc. Vacunas recombinantes del virus de la lengua azul y sus utilizaciones
WO2012030720A1 (en) 2010-08-31 2012-03-08 Merial Limited Newcastle disease virus vectored herpesvirus vaccines
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
EP2694678A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
HK1200329A1 (en) 2011-04-25 2015-08-07 先进生物学实验室股份有限公司 Truncated hiv envelope proteins (env), methods and compositions related thereto
ES2764079T3 (es) 2011-05-27 2020-06-02 Boehringer Ingelheim Animal Health Usa Inc Vacunas genéticas contra el virus Hendra y el virus Nipah
CA2837375C (en) 2011-06-01 2019-07-16 Merial Limited Needle-free administration of prrsv vaccines
SI2741740T1 (sl) 2011-08-12 2017-08-31 Merial, Inc. Vakuumsko konzerviranje bioloških proizvodov, zlasti cepiv
EP3251691B1 (en) * 2011-11-30 2019-11-20 Boehringer Ingelheim Animal Health USA Inc. Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
EP3466443B1 (en) 2012-02-14 2020-12-16 Boehringer Ingelheim Animal Health USA Inc. Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
ES2632429T3 (es) 2012-02-14 2017-09-13 Merial, Inc. Vacunas subunitarias de rotavirus y procedimientos para la fabricación y utilización de las mismas
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
ES2664069T3 (es) 2012-06-13 2018-04-18 Merial, Inc. Vacunas contra BTV y AHSV de genoma reordenado
WO2014164697A1 (en) 2013-03-12 2014-10-09 Merial Limited Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
ES2690836T3 (es) 2014-05-19 2018-11-22 Merial, Inc. Dispositivo para la inyección in ovo condicional
IL241841B (en) * 2014-09-30 2019-09-26 Univ Free State Production of proteins for human and animal health using yarrowia lipolytica
CA2966191A1 (en) 2014-11-03 2016-05-12 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
CN104881148B (zh) * 2015-05-15 2017-12-15 苏州达方电子有限公司 键盘及其控制方法
DK3313864T3 (da) 2015-06-23 2021-11-01 Boehringer Ingelheim Animal Health Usa Inc Rekombinante virusvektorer indeholdende prrsv minor protein og fremgangsmåder til fremstilling og anvendelse deraf
WO2017031120A1 (en) 2015-08-20 2017-02-23 Merial, Inc. Fcv recombinant vaccines and uses thereof
FI3355915T3 (fi) 2015-09-29 2024-01-12 Boehringer Ingelheim Animal Health Usa Inc Koirien parvoviruksen (CPV) viruksen kaltaisten hiukkasten (VLP) rokotteet ja niiden käytöt
MA42640B1 (fr) 2015-11-23 2021-06-30 Merial Inc Protéines de fusion de dmdv et e2 et leurs utilisations
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
CN107099513B (zh) * 2017-06-22 2020-07-14 北京邦卓生物科技有限公司 一种共表达ndv hn和ibdv vp2基因的hvt的构建及其应用
CN110777122A (zh) * 2019-10-21 2020-02-11 青岛易邦生物工程有限公司 一种表达ibdv的vp2蛋白的重组ⅰ型马立克氏病病毒
CN116298278A (zh) * 2023-04-18 2023-06-23 浙江大学 一种用于传染性支气管炎病毒中和抗体检测的elisa试剂盒及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643216B2 (en) * 1989-05-30 1993-11-11 Commonwealth Scientific And Industrial Research Organisation Production of IBDV VP2 in highly immunogenic form
CA2110505A1 (en) * 1991-07-26 1993-02-18 Enzo Paoletti Infectious bursal disease virus recombinant poxvirus vaccine
FR2697534A1 (fr) * 1992-11-02 1994-05-06 Rhone Merieux Virus herpès de la dinde recombinant pour la réalisation de vaccin de la maladie de Gumboro, son procédé de préparation et vaccin obtenu.
EP0620277A1 (en) * 1993-03-18 1994-10-19 Merck & Co. Inc. Nucleic acid pharmaceuticals
EP0690912B1 (en) * 1993-04-14 2008-03-05 Commonwealth Scientific And Industrial Research Organisation Recombinant avian adenovirus vector
ATE475668T1 (de) * 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
JPH08116976A (ja) * 1994-10-20 1996-05-14 Chemo Sero Therapeut Res Inst 免疫用核酸調製物およびこれを用いた免疫方法
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
AU4489896A (en) * 1994-12-30 1996-07-24 Rhone Merieux Avian recombinant live vaccine
FR2728794B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
FR2751225B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
US5916879A (en) 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
US6468984B1 (en) * 1999-06-08 2002-10-22 Innovo Biotechnologies Ltd. DNA vaccine for protecting an avian against infectious bursal disease virus

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102719567A (zh) * 2012-07-05 2012-10-10 广东温氏食品集团有限公司 禽传染性支气管炎病毒h120毒株的pcr检测引物及检测方法
CN111727053A (zh) * 2018-01-26 2020-09-29 全国农业协同组合连合会 非人动物用抗原表面结合型脂质体疫苗
CN111727053B (zh) * 2018-01-26 2024-06-25 全国农业协同组合连合会 非人动物用抗原表面结合型脂质体疫苗
US12220458B2 (en) 2018-01-26 2025-02-11 National Federation Of Agricultural Cooperative Associations Antigen-surface-coupled liposome vaccine for non-human animals
CN115089700A (zh) * 2022-05-25 2022-09-23 永州中古生物技术有限公司 一种抗β属冠状病毒的疫苗组合物及其应用

Also Published As

Publication number Publication date
CO4700304A1 (es) 1998-12-29
US6221362B1 (en) 2001-04-24
EP0914442B1 (fr) 2004-09-22
EP0914442A1 (fr) 1999-05-12
NZ333779A (en) 2000-07-28
TNSN97120A1 (fr) 2005-03-15
HUP9902790A3 (en) 2000-03-28
CN1225685A (zh) 1999-08-11
US20020037292A1 (en) 2002-03-28
AR013063A1 (es) 2000-12-13
ES2232876T3 (es) 2005-06-01
AU3773697A (en) 1998-02-10
US20030124145A1 (en) 2003-07-03
CA2261343A1 (fr) 1998-01-29
ID19475A (id) 1998-07-16
DE69730839D1 (de) 2004-10-28
HU224830B1 (en) 2006-02-28
AU735184B2 (en) 2001-07-05
BR9710495A (pt) 1999-08-17
WO1998003659A1 (fr) 1998-01-29
DE69730839T2 (de) 2005-09-29
FR2751225A1 (fr) 1998-01-23
JP2009149608A (ja) 2009-07-09
HUP9902790A2 (hu) 1999-12-28
FR2751225B1 (fr) 1998-11-27
US6464984B2 (en) 2002-10-15
JP2001503019A (ja) 2001-03-06
KR20000065258A (ko) 2000-11-06
MA24268A1 (fr) 1998-04-01
EP1523992A1 (fr) 2005-04-20

Similar Documents

Publication Publication Date Title
CN1701788A (zh) 禽多核苷酸疫苗制剂
CN1289674C (zh) Dna疫苗－pcv
CN1056878C (zh) 重组火鸡疱疹病毒及其衍生的活载体疫苗
CN1678345A (zh) 制备流感病毒的多质粒系统
CN1846786A (zh) 与佐剂一起注射的重组活疫苗
CA2252375C (en) Nucleic acid vaccination for parvoviral infections
CN1171814A (zh) 多核苷酸结核病疫苗
CN1829799A (zh) 含polii启动子和核酶的重组流感载体
CN1606624A (zh) 疫苗
JP2010187679A (ja) 新規な組換えヘルペスウイルスおよび変異体ヘルペスウイルス
CN1764474A (zh) 免疫原性组合物及方法
WO1998022145A9 (en) Immunization of infants
PL210451B1 (pl) Szczepionka DNA przeciwko wirusowi nosówki psów (CDV)
CN1925870A (zh) 表达马－2型流感病毒ha1的dna疫苗
CN1441842A (zh) 通过重排其基因操纵负链rna病毒及其用途
CN1774264A (zh) 重组火鸡疱疹病毒及其应用
CN1192799C (zh) 佐剂组合制剂
CN1533242A (zh) 口蹄疫病毒疫苗
CN1653182A (zh) 重组禽痘病毒
CN1570115A (zh) 优化的sars冠状病毒刺突蛋白基因
CN116102660A (zh) 一种猪细小病毒基因工程表位疫苗及其制备方法
CN1404398A (zh) 用于生产型动物的改良dna疫苗
CN1171636C (zh) 一种乙型肝炎dna疫苗
CN1245217C (zh) 一种包含dna疫苗和灭活狂犬病毒的疫苗制剂
CN1764718A (zh) 表达典型和变异ibdv株系特异性的病毒中和表位的传染性法氏囊病病毒(i bdv)突变株

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1083448

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1083448

Country of ref document: HK